Core Insights - The company reported a third-quarter revenue of 113 million yuan, representing a year-on-year increase of 2.01% [1] - The net profit for the third quarter was 31.54 million yuan, showing a significant year-on-year growth of 70.32% [1] - For the first three quarters, the total revenue was 313 million yuan, which reflects a year-on-year decline of 2.28% [1] - The net profit for the first three quarters reached 61.31 million yuan, marking a year-on-year increase of 66.33% [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥113,403,982.37, representing a 2.01% increase year-over-year[5] - Net profit attributable to shareholders reached ¥31,539,981.40, a significant increase of 70.32% compared to the same period last year[5] - The basic earnings per share (EPS) was ¥0.1116, reflecting a 111.27% increase year-over-year[5] - Total operating revenue for the current period is ¥313,186,310.64, a decrease of 2.6% from ¥320,487,166.95 in the previous period[23] - Net profit for the current period increased to ¥68,037,956.73, up 56.5% from ¥43,514,466.94 in the previous period[24] - Operating profit rose to ¥73,225,485.50, an increase of 45.3% compared to ¥50,370,590.19 last year[24] - Basic and diluted earnings per share improved to ¥0.2169 from ¥0.1310, representing a growth of 65.0%[25] - The company reported a total comprehensive income of ¥68,366,542.10, an increase from ¥43,712,115.15 in the previous period[24] Cash Flow and Investments - The company reported a net cash flow from operating activities of ¥43,571,621.89, which decreased by 17.47% year-to-date[5] - Net cash flow from operating activities decreased to ¥43,571,621.89 from ¥52,792,147.53, a decline of 17.0%[26] - Net cash flow from investment activities was -¥76,034,669.92, an improvement of 71.91% compared to the previous year[10] - Net cash flow from investing activities was negative at -¥76,034,669.92, compared to -¥270,707,822.91 in the previous period[26] - Cash and cash equivalents decreased by 60.76% to ¥127,548,458.93, primarily due to the redemption of financial products[10] - Cash and cash equivalents at the end of the period totaled ¥63,170,937.84, down from ¥78,499,122.64[26] - The company experienced a 38.52% decline in cash inflow from investment activities, totaling ¥199,873,585.83[10] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,159,392,689.56, up 2.12% from the end of the previous year[5] - The total assets as of September 30, 2025, amounted to CNY 1,159,392,689.56, an increase from CNY 1,135,302,801.42 at the beginning of the period[19] - Current assets totaled CNY 454,175,682.65, up from CNY 428,260,564.52 at the start of the period, reflecting a growth of approximately 6.7%[20] - Total liabilities decreased to CNY 117,631,201.42 from CNY 134,900,451.15, a reduction of about 12.8%[22] - The company's total liabilities decreased by 46.39% in tax payable, amounting to ¥4,916,427.23, due to the payment of last year's corporate income tax[8] - The company's total liabilities to equity ratio improved to approximately 11.3% from 13.5%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,766[11] - The largest shareholder, Pengwei International Group (Hong Kong) Limited, holds 19.98% of shares, totaling 56,482,150 shares[12] - Ganzhou Yingbei Investment Development Co., Ltd. holds 16.12% of shares, totaling 45,566,272 shares[12] - The third-largest shareholder, Shan Senlin, holds 10.49% of shares, totaling 29,649,123 shares, with 22,236,842 shares pledged[12] - The top ten shareholders collectively hold significant stakes, with the first three alone accounting for 46.59% of total shares[12] - The company has no preferred shareholders or changes in restricted shares during the reporting period[13] - There are no changes in the participation of the top ten shareholders in margin financing and securities lending[12] - The company has a total of 0 shares with restored voting rights for preferred shareholders[11] - The report indicates no involvement in securities lending by the top ten shareholders[12] - The company has not disclosed any relationships or concerted actions among the top shareholders beyond the known associations[12] Inventory and Equity - The company’s inventory rose to CNY 106,039,684.36 from CNY 104,889,048.93, showing a slight increase of about 1.1%[20] - The total equity increased to CNY 1,041,761,488.14 from CNY 1,000,402,350.27, reflecting a growth of approximately 4.1%[22] - The company held long-term equity investments valued at CNY 251,007,184.57, down from CNY 258,790,489.13, indicating a decrease of approximately 3.0%[20] Corporate Governance - The company plans to hold its first extraordinary general meeting on September 30, 2025, to discuss amendments to the articles of association[17] - The company has not undergone an audit for the third quarter financial report[27]

Group 1 - The recent reduction plans by major shareholders of companies like Keli'er, United Precision, and Senba Sensor have raised concerns among investors, especially given the high market valuations and stock prices [1] - Historical cases show that announcements of share reductions by major shareholders at high stock prices often lead to significant declines in those companies' stock prices shortly after [1] - The actions of major shareholders are seen as a direct endorsement of the company's value, and their decisions can significantly impact investor confidence [2] Group 2 - There is a concern that some major shareholders act more like traders rather than guardians of the company, which can negatively affect the confidence of retail investors [2] - A healthy capital market relies on the confidence of all participants, and major shareholders are expected to demonstrate responsibility and commitment to the company's long-term growth [2] - The reputation and market value of a company, as well as the overall health of the capital market, are influenced by the actions and attitudes of its major shareholders [2]

证券代码：300701 证券简称：森霸传感 公告编号：2025-053 森霸传感科技股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 2. 会议召开地点：河南省南阳市社旗县城关镇本公司会议室。 3. 会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式。 4. 会议召集人：公司董事会。 5. 会议主持人：董事长单森林先生。 一、会议召开和出席情况 （一）会议召开情况 1. 会议召开时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为2025年9月30日9： 15-9：25，9:30-11:30，13:00-15:00； ②通过深圳证券交易所互联网投票系统进行网络投票的具体时间为2025年9 月30日9:15-15:00。 6. 本次股东大会会议的召集、召开与表决程序符合《公司法》《上市公司股 东会规则》等相关法律法规和《公司章程》的规定。 （二）出席情况 1. 出席本次会议的股东及股东代表共 1 ...

森霸传感科技股份有限公司 证券代码：300701 证券简称：森霸传感 公告编号：2025-054 截至本公告日，白旭春先生未直接持有公司股份且不存在应当履行而未履行 的承诺事项。白旭春先生在任职期间勤勉尽责，为促进公司规范运作和持续发展 发挥了积极作用，公司对其在任职期间为公司发展所做的贡献表示衷心感谢！ 二、关于选举职工代表董事的情况 根据《公司法》《上市公司章程指引》《深圳证券交易所上市公司自律监管指 引第 2 号—创业板上市公司规范运作》等法律法规及规范性文件及《公司章程》 1 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 森霸传感科技股份有限公司(以下简称"公司")根据《公司法》《上市公司章程 指引》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号—创业板上市公司规范运作》《关于新<公司法>配套制度规则实施 相关过渡期安排》等法律法规及规范性文件的有关规定，公司于 2025 年 9 月 30 日召开 2025 年第一次临时股东大会，审议通过了《关于修订<公司章程>及相关 议事规则的议案》 ...

上海精诚磐明律师事务所 上海环球金融中心15楼T61-T80 邮政编码: 200120 中国上海市浦东新区世纪大道100号 Brightstone Lawyers Suite T61-T80, 15/F, Shanghai World Financial Center No.100 Century Avenue, Pudong New District Shanghai 200120, China Tel 电话: +86 21 6881 5499 www.brightstonelawyers.com 致：森霸传感科技股份有限公司 上海精诚磐明律师事务所 关于森霸传感科技股份有限公司 2025 年第一次临时股东大会的法律意见书 1 一. 关于本次股东大会的召集和召开程序 经本所律师查验： 1. 本次股东大会系由公司第五届董事会第十二次会议审议决定召集。 森霸传感科技股份有限公司（下称"公司"）2025 年第一次临时股东大会（下称"本 次股东大会"）于 2025 年 9 月 30 日在河南省南阳市社旗县城关镇公司会议室如期召开。 上海精诚磐明律师事务所（下称"本所"）接受公司的委托，指派沈盈欣律师、杨露律师 （以 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Viewpoint - The company Senba Sensor (300701.SZ) announced a share reduction plan by its actual controller's concerted action party, Shanghai Tongyi Investment Management Co., Ltd., specifically the Tongyi Kangteng No. 8 Private Securities Investment Fund, which plans to reduce its holdings of 3,086,930 shares, accounting for 1.09% of the total share capital, within a specified period [1]. Summary by Relevant Sections - **Share Reduction Plan** The Tongyi Kangteng No. 8 fund intends to reduce its holdings through centralized bidding and block trading, with a maximum reduction of 3,086,930 shares, equivalent to 1.09% of the total share capital, within three months starting from October 29, 2025 [1]. - **Financial Impact** Based on the closing price of 13.30 yuan on September 29, the total amount from the planned reduction could reach up to 41.06 million yuan [1]. The fund initially held 698,000 shares, representing 0.39% of the total share capital, and has cumulatively reduced its holdings by 2,313,100 shares, realizing approximately 26.22 million yuan [1][2]. - **Historical Reduction Data** The fund's previous reductions include a total of 2,313,100 shares sold at an average price ranging from 9.44 yuan to 12.16 yuan per share, with total cash proceeds of approximately 45.70 million yuan to 52.01 million yuan [3][4].

Group 1 - The core point of the article is that Senba Sensor (300701.SZ) experienced a decline of 4.06%, closing at 12.76 yuan, with a trading volume of 200 million yuan and a market capitalization of 3.6 billion yuan [1] - The company announced that one of its actual controllers, Shanghai Tongyi Investment Management Co., Ltd., through its Tongyi Kangteng No. 8 Private Securities Investment Fund, plans to reduce its holdings by up to 3,086,930 shares, which represents no more than 1.09% of the company's total share capital, within three months after 15 trading days from the announcement date [1]

Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]